Evidence map›Paper›PMID 30660179›Full record

ArticleJournal of nanobiotechnology2019

Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albumin-QDs nano-hybrids: covalent coupling and phospholipid complexation approaches.

Dina G Zayed, Shaker M Ebrahim, Maged W Helmy, Sherine N Khattab, Mohammed Bahey-El-Din, Jia-You Fang, Kadria A Elkhodairy, Ahmed O Elzoghby

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Nanoparticle Drug Delivery Systems for α-Mangostin.Nanotechnology, science and applications · 2020
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Dina G ZayedCancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
Shaker M EbrahimDepartment of Materials Science, Institute of Graduate Studies and Research, Alexandria University, Alexandria, 21526, Egypt.
Maged W HelmyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Damanhour University, Damanhur, Egypt.
Sherine N KhattabCancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
Mohammed Bahey-El-DinDepartment of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
Jia-You FangPharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Taoyuan, 333, Taiwan. fajy@mail.cgu.edu.tw.
Kadria A ElkhodairyCancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
Ahmed O ElzoghbyCancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. aelzoghby@bwh.harvard.edu.
Alexandria University · EGChang Gung University · TWDamanhour University · EG

Funding

Ministry of Science and Technology, Taiwan 105-2320-B-182-010-MY3Ministry of Scientific Research, Egypt 15053
6 · The paper itself

Abstract

backgroundThe rationale of this study is to combine the merits of both albumin nanoparticles and quantum dots (QDs) in improved drug tumor accumulation and strong fluorescence imaging capability into one carrier. However, premature drug release from protein nanoparticles and high toxicity of QDs due to heavy metal leakage are among challenging hurdles. Following this platform, we developed cancer nano-theranostics by coupling biocompatible albumin backbone to CdTe QDs and mannose moieties to enhance tumor targeting and reduce QDs toxicity. The chemotherapeutic water soluble drug pemetrexed (PMT) was conjugated via tumor-cleavable bond to the albumin backbone for tumor site-specific release. In combination, the herbal hydrophobic drug resveratrol (RSV) was preformulated as phospholipid complex which enabled its physical encapsulation into albumin nanoparticles.

resultsAlbumin-QDs theranostics showed enhanced cytotoxicity and internalization into breast cancer cells that could be traced by virtue of their high fluorescence quantum yield and excellent imaging capacity. In vivo, the nanocarriers demonstrated superior anti-tumor effects including reduced tumor volume, increased apoptosis, and inhibited angiogenesis in addition to non-immunogenic response. Moreover, in vivo bioimaging test demonstrated excellent tumor-specific accumulation of targeted nanocarriers via QDs-mediated fluorescence.

conclusionMannose-grafted strategy and QD-fluorescence capability were beneficial to deliver albumin nanocarriers to tumor tissues and then to release the anticancer drugs for killing cancer cells as well as enabling tumor imaging facility. Overall, we believe albumin-QDs nanoplatform could be a potential nano-theranostic for bioimaging and targeted breast cancer therapy.

Indexed as

AlbuminsAntineoplastic AgentsQuantum DotsAnimalsBreast NeoplasmsCell Line, TumorCombined Modality TherapyDrug Therapy, CombinationFemaleHumansHydrophobic and Hydrophilic InteractionsMice, Inbred BALB CMolecular Targeted TherapyOptical ImagingPhytotherapyAlbuminsAntineoplastic AgentsAlbumin nanoparticlesBreast cancerMannose targetingPemetrexedQDsResveratrolTheranostics

Identifiers

PMID30660179
PMCPMC6339697
OpenAlexW2908626547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.